Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $146.00

Merck & Co., Inc. (NYSE:MRK) had its price objective upped by Guggenheim from $145.00 to $146.00 in a research report sent to investors on Wednesday, MarketBeat.com reports. Guggenheim currently has a buy rating on the stock.

Several other research firms have also recently commented on MRK. Morgan Stanley boosted their price objective on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Barclays upped their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Bank of America lifted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Thirteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $134.56.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $128.61 on Wednesday. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The firm has a market cap of $317.64 billion, a PE ratio of 102.89, a price-to-earnings-growth ratio of 5.53 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The business has a fifty day moving average of $123.98 and a 200-day moving average of $119.11.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company’s revenue was up 5.1% on a year-over-year basis. During the same period last year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Insider Activity at Merck & Co., Inc.

In related news, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This represents a 24.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 86,553 shares of company stock worth $11,177,945. Company insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC grew its holdings in shares of Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after buying an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC increased its position in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC raised its holdings in Merck & Co., Inc. by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after acquiring an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC raised its holdings in Merck & Co., Inc. by 22.2% in the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after acquiring an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Merck & Co., Inc. by 111.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after acquiring an additional 359,356 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.